Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | FIH study of bavdegalutamide in metastatic castrate-resistant prostate cancer

Sunandana Chandra • 11 Jun 2020
ASCO 2020
Prostate Cancer Abiraterone Bavdegalutamide Enzalutamide

Sunandana Chandra, MD, MS, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, discusses data from a first in human study of bavdegalutamide, an androgen receptor PROTAC degrader in patients with metastatic castrate-resistant prostate cancer following enzalutamide and/or abiraterone. The study showed an acceptable safety profile and clinical activity in these patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Sunandana Chandra

Challenges in treatment strategies for symptomatic brain metastases in melanoma
3:15
Challenges in treatment strategies for symptomatic brain metastases in melanoma
Sunandana Chandra • 12 Jun 2024
Repurposing irinotecan
3:14
Repurposing irinotecan
Sunandana Chandra • 11 Jun 2020
Intrathecal + IV nivo for metastatic melanoma with leptomeningeal disease
2:47
Intrathecal + IV nivo for metastatic melanoma with leptomeningeal disease
Sunandana Chandra • 16 Jun 2020
Toripalimab + axitinib in patients with metastatic mucosal melanoma
2:19
Toripalimab + axitinib in patients with metastatic mucosal melanoma
Sunandana Chandra • 15 Jun 2020

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals